Trial Profile

A randomized, placebo-controlled, multicenter phase IIb trial for Parkinson's disease (Monotherapay) in Treatment-naive patients associated with long COVID.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Nov 2024 According to a BioVie media release, company announced that an abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st & 22nd 2024, in Barcelona Spain.
23 Oct 2024 According to a BioVie media release, company announced that the launching a Phase 2b trial for PD in late 2024 or early 2025.
16 Sep 2024 According to a BioVie media release, company announced that the OHRO has approved BioVies plan to evaluate bezisterim and FDA had previously reviewed and approved the study as Safe to Proceed in August 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com